Yangchun Xin1,2, Xiaofei Gao3, Li Liu1, Woo-Ping Ge3, Manoj K Jain4, Hancheng Cai5,6,7. 1. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. 2. Katzin Diagnostic & Research PET/MR Center, Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE, 19803, USA. 3. Children's Research Institute, Department of Pediatrics, Neuroscience, Neurology & Neurotherapeutics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. 4. Department of Radiology, Mayo Clinic, Jacksonville, FL, 32224, USA. 5. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. cai.hancheng@mayo.edu. 6. Department of Radiology, Mayo Clinic, Jacksonville, FL, 32224, USA. cai.hancheng@mayo.edu. 7. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. cai.hancheng@mayo.edu.
Abstract
PURPOSE: Fluorine-18 labeled tryptophan analog L-1-[18F]fluoroethyl-tryptophan (L-1-[18F]FETrp) was designed for positron emission tomography (PET) imaging of cancer by dual targeting of the overexpressed amino acid transporters and altered indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pathway of tryptophan metabolism. In our previous study, we described the radiosynthesis and preliminary evaluation of L-1-[18F]FETrp for PET imaging of breast cancer. The aim of this study was to investigate the in vivo imaging mechanism and further evaluate this radiotracer in more wide range types of cancers including prostate cancer, lung cancer, and glioma. PROCEDURES: The mice bearing subcutaneous PC-3 prostate cancer, subcutaneous H2009 and H460 lung cancers, subcutaneous MDA-MB-231, orthotopic A549 lung cancer, and intracranial 73C glioma were employed to evaluate L-1-[18F]FETrp for PET imaging of cancer. The in vivo catabolism of L-1-[18F]FETrp in the tumor was studied by analysis of PC-3 extracts with radio-HPLC. RESULTS: Small animal PET/CT imaging of L-1-[18F]FETrp visualized all tumors in these different mouse models with high accumulations of radioactivity in PC-3 (7.5 ± 0.6 % ID/g), H2009 (5.3 ± 0.8 % ID/g), H460 (9.0 ± 1.4 % ID/g), A549 (4.5 ± 0.5 % ID/g), and 73C (4.1 ± 0.7 % ID/g) tumors. The radio-HPLC analysis of PC-3 tumor extracts revealed that about 30 % of L-1-[18F]FETrp was converted into a highly polar radioactive metabolite. The uptake in H460 cancer was about 1.7-fold higher than that in H2009 cancer, which indicated L-1-[18F]FETrp could differentiate these subtypes of lung cancers (H2009 and H460) by imaging quantification. Furthermore, small animal PET/CT imaging in intracranial glioma revealed L-1-[18F]FETrp could pass blood-brain barrier (BBB) and accumulate in glioma with a favorable imaging contrast (tumor-to-brain 2.9). CONCLUSIONS: L-1-[18F]FETrp highly accumulated in a wide range of malignancies including lung cancer, prostate cancer, and glioma. These results suggested that L-1-[18F]FETrp is a promising radiotracer for PET imaging of cancer.
PURPOSE:Fluorine-18 labeled tryptophan analog L-1-[18F]fluoroethyl-tryptophan (L-1-[18F]FETrp) was designed for positron emission tomography (PET) imaging of cancer by dual targeting of the overexpressed amino acid transporters and altered indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pathway of tryptophan metabolism. In our previous study, we described the radiosynthesis and preliminary evaluation of L-1-[18F]FETrp for PET imaging of breast cancer. The aim of this study was to investigate the in vivo imaging mechanism and further evaluate this radiotracer in more wide range types of cancers including prostate cancer, lung cancer, and glioma. PROCEDURES: The mice bearing subcutaneous PC-3 prostate cancer, subcutaneous H2009 and H460 lung cancers, subcutaneous MDA-MB-231, orthotopic A549 lung cancer, and intracranial 73C glioma were employed to evaluate L-1-[18F]FETrp for PET imaging of cancer. The in vivo catabolism of L-1-[18F]FETrp in the tumor was studied by analysis of PC-3 extracts with radio-HPLC. RESULTS: Small animal PET/CT imaging of L-1-[18F]FETrp visualized all tumors in these different mouse models with high accumulations of radioactivity in PC-3 (7.5 ± 0.6 % ID/g), H2009 (5.3 ± 0.8 % ID/g), H460 (9.0 ± 1.4 % ID/g), A549 (4.5 ± 0.5 % ID/g), and 73C (4.1 ± 0.7 % ID/g) tumors. The radio-HPLC analysis of PC-3 tumor extracts revealed that about 30 % of L-1-[18F]FETrp was converted into a highly polar radioactive metabolite. The uptake in H460 cancer was about 1.7-fold higher than that in H2009 cancer, which indicated L-1-[18F]FETrp could differentiate these subtypes of lung cancers (H2009 and H460) by imaging quantification. Furthermore, small animal PET/CT imaging in intracranial glioma revealed L-1-[18F]FETrp could pass blood-brain barrier (BBB) and accumulate in glioma with a favorable imaging contrast (tumor-to-brain 2.9). CONCLUSIONS:L-1-[18F]FETrp highly accumulated in a wide range of malignancies including lung cancer, prostate cancer, and glioma. These results suggested that L-1-[18F]FETrp is a promising radiotracer for PET imaging of cancer.
Entities:
Keywords:
Cancer imaging; IDO; Kynurenine pathway; PET; Tryptophan metabolism
Authors: Jean Henrottin; Astrid Zervosen; Christian Lemaire; Frédéric Sapunaric; Sophie Laurent; Benoit Van den Eynde; Serge Goldman; Alain Plenevaux; André Luxen Journal: ACS Med Chem Lett Date: 2015-01-25 Impact factor: 4.345
Authors: Sharon K Michelhaugh; Otto Muzik; Anthony R Guastella; Neil V Klinger; Lisa A Polin; Hancheng Cai; Yangchun Xin; Thomas J Mangner; Shaohui Zhang; Csaba Juhász; Sandeep Mittal Journal: J Nucl Med Date: 2016-10-20 Impact factor: 10.057
Authors: Stefanie D Krämer; Linjing Mu; Adrienne Müller; Claudia Keller; Olga F Kuznetsova; Christian Schweinsberg; Dominic Franck; Cristina Müller; Tobias L Ross; Roger Schibli; Simon M Ametamey Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Aristeidis Chiotellis; Adrienne Müller Herde; Simon L Rössler; Ante Brekalo; Erika Gedeonova; Linjing Mu; Claudia Keller; Roger Schibli; Stefanie D Krämer; Simon M Ametamey Journal: J Med Chem Date: 2016-05-26 Impact factor: 7.446
Authors: Jean Henrottin; Christian Lemaire; Dominique Egrise; Astrid Zervosen; Benoit Van den Eynde; Alain Plenevaux; Xavier Franci; Serge Goldman; André Luxen Journal: Nucl Med Biol Date: 2016-03-11 Impact factor: 2.408
Authors: Peter Wierstra; Gerwin Sandker; Erik Aarntzen; Martin Gotthardt; Gosse Adema; Johan Bussink; René Raavé; Sandra Heskamp Journal: EJNMMI Radiopharm Chem Date: 2019-11-06
Authors: Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923